Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
New Ver. of CN Medical Insurance Drug List Adds 91 Drugs, Expected to Cut Patient Burden by RMB50B+ Next Yr
Recommend 20 Positive 34 Negative 9 |
||||
|
||||
|
China's National Healthcare Security Administration announced a new version of the medical insurance drug list at a press conference this morning. The application requirements for adjustments to this year's medical insurance drug list primarily included drugs newly marketed or with revised instructions in the past five years, orphan drugs, pediatric drugs and generics encouraged by the country, as well as essential national medicines. Through the appropriate procedures, a total of 91 new drugs have been added in this adjustment, including 26 oncology drugs and 15 drugs for chronic diseases such as diabetes. In this year's negotiation/bidding phase, 117 drugs outside the list participated, with 89 successfully negotiated/bid, achieving a success rate of 76% and an average price reduction of 63%, overall comparable to 2023. The new version of the Chinese medical insurance drug list will be officially implemented from next year. With the combined effects of negotiated price reductions and health insurance reimbursements, it is expected to reduce the burden on patients by over RMB50 billion in 2025. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
